Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 72 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug Saf 2017;40:855-69. [Ref.ID 102075]
2. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
5. Cita con resumen
6. Cita con resumen
Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn S, Dreyer AN. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol 2017;83:884-93. [Ref.ID 101970]
7.Enlace a cita original Cita con resumen
Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiol Drug Saf 2017:26 de marzo. [Ref.ID 101903]
8. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
9. Cita con resumen
Spelsberg A , Prugger C , Doshi P , Ostrowski K , Witte T , Hüsgen D , Keil U , for the Working Group on Health and Working Group on Freedom of Information Transparency International Deutschland eV. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017;356:j337. [Ref.ID 101390]
10. Cita con resumen
11.Tiene citas relacionadas Cita con resumen
Eichler H-G, Hurts H, Broich K, Rasi G. Drug regulation and pricing — Can regulators influence affordability?. N Engl J Med 2016;374:1807-9. [Ref.ID 100113]
12. Cita con resumen
Anónimo. GAO finds gaps In FDA’s drug-tracking system. DIA Daily 2016:15 de enero. [Ref.ID 99971]
13. Cita con resumen
Moore TJ, Furberg CD. Electronic health data for postmarket surveillance: a vision not realized. Drug Saf 2015;38:601-10. [Ref.ID 99852]
14. Cita con resumen
Anónimo. What next for the malaria RTS,S vaccine candidate?. Lancet 2015;386:1708. [Ref.ID 99666]
15. Cita con resumen
Anónimo. Drug problems: dangerous decision-making at the FDA. POGO. Project on Government Oversight 2015:15 de octubre. [Ref.ID 99569]
16. Cita con resumen
Dyer O. Drug maker must restart obesity drug study after releasing early data. BMJ 2015;350:h2844. [Ref.ID 99103]
17. Cita con resumen
Herman O. FDA advisers vote to keep black-box warning on Chantix. Journal Watch 2014:20 de octubre. [Ref.ID 98122]
18. Cita con resumen
Anónimo. Xolair (omalizumab): drug safety communication - Slightly elevated risk of cardiovascular and cerebrovascular serious adverse events. FDA U.S. Food and Drug Administration 2014:26 de septiembre. [Ref.ID 97997]
19. Cita con resumen
Anónimo. FDA approves naloxegol for opioid-induced constipation. DIA Daily 2014:17 de septiembre. [Ref.ID 97910]
Seleccionar todas
 
 1 a 20 de 72 siguiente >>